MedTrace Logo

Lorcaserin and Behavioral Modification for Overweight and Obesity Management in Chinese Obese Patients

NCT03720574 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-05-02

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and weight loss effect of lorcaserin at the end of the first year of treatment (Week 48) in overweight and Chinese adult obese patients compared to placebo.

Conditions

Interventions

DRUG

Lorcaserin 10 mg BID

Lorcaserin 10 mg tablet each morning and evening for a duration of 48 weeks

DRUG

Matching Placebo BID

Matching Placebo tablet each morning and evening for a duration of 48 weeks

Sponsors & Collaborators

  • Kanion & Huawe Medicine Co.,Ltd

    lead INDUSTRY

Principal Investigators

  • Xiaohui Guo, Ph. D · Peking University First Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-17
Primary Completion
2020-12-06
Completion
2020-12-12

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03720574 on ClinicalTrials.gov